0001104659-20-121584.txt : 20201105 0001104659-20-121584.hdr.sgml : 20201105 20201105074052 ACCESSION NUMBER: 0001104659-20-121584 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 201288722 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 8-K 1 tm2035067d1_8k.htm FORM 8-K
0001322505 false 0001322505 2020-10-05 2020-10-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 5, 2020

 

 

 

ALBIREO PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware
(State or other jurisdiction of
incorporation)		   001-33451
(Commission File
Number)		   90-0136863
(IRS Employer
Identification No.)
         
10 Post Office Square, Suite 1000
Boston, Massachusetts
(Address of principal executive offices)		       02109
(Zip Code)

 

(857) 254-5555

Registrant’s telephone number, including area code

 

Not applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered		  
Common Stock   ALBO   The Nasdaq Capital Market  

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 5, 2020, Albireo Pharma, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2020 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)       Exhibits

 

The following exhibit is furnished with this report:

 

Exhibit
Number		   Description
99.1   Press release dated November 5, 2020
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALBIREO PHARMA, INC.
   
Date: November 5, 2020 /s/ Ronald H.W. Cooper
  Ronald H.W. Cooper
  President and Chief Executive Officer

 

3

 

 EX-99.1 2 tm2035067d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Albireo Reports Q3 2020 Financial Results and Provides Business Update

 

- Positive Phase 3 data for odevixibat in PFIC with filings on track for no later than early 2021 -

 

- Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting -

 

- Introduces new and novel bile acid modulator A3907 at AASLD -

 

- Raised $160 million in gross proceeds in public offering of 4,000,000 shares -

 

- Company to host post-AASLD Business Update Call on Tuesday, November 17, 2020 -

 

 

BOSTON, MA — November 5, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the third quarter ended September 30, 2020.

 

“There is great excitement around our very positive data and late breaker acceptance for PEDFIC 1, the largest global Phase 3 clinical trial in PFIC,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We are moving to a new stage for Albireo, anticipating regulatory approval, priority review voucher issuance and launch in the second half of next year, while deepening our pipeline with Phase 3 trials in biliary atresia and Alagille syndrome and advancing A3907 in adult liver diseases.”

 

Recent and Upcoming Highlights

 

Odevixibat

 

·Achieved high statistical significance on both the U.S. and EU primary endpoints for PEDFIC 1, the largest ever global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat. The study demonstrated sustained reductions in bile acids and pruritus, improved growth parameters, and was well tolerated with very low incidence of diarrhea for both PFIC1 and PFIC2 children. Positive results from the trial were announced on September 8, 2020: News Release: Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC.
  
·On track to complete regulatory filings in the U.S. and EU no later than early 2021, in anticipation of potential regulatory approval, issuance of a rare pediatric disease priority review voucher and launch of odevixibat in the second half of 2021.
  
·Announced late-breaker acceptances at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting Digital Experience™ (TLMdX), being held November 13-16. News Release: Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers. The full data set from the PEDFIC 1 trial will be presented. There will also be a late breaker poster session for interim results from PEDFIC 2, the open-label Phase 3 extension study of the long-term efficacy and safety of odevixibat in children with PFIC.
  
·BOLD, the second Phase 3 trial with odevixibat, continues to activate new sites and enroll patients despite COVID-19 challenges. Biliary atresia is the most common pediatric cholestatic liver disease, and the number one cause of liver transplantation in children.
  
·On track to initiate third Phase 3 trial of odevixibat in Alagille syndrome by the end of 2020.

 

 

 

 

Early Stage Pipeline

 

·Preclinical development programs are progressing in adult liver disease and the Company expects to complete IND-enabling studies for a new lead preclinical candidate A3907 this year. The Company will present adult liver disease data at the upcoming AASLD meeting on November 13-16, 2020. News Release: Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers.

 

Corporate

 

·Completed an underwritten public offering of 4,000,000 shares of common stock at a price of $40.00 per share. The net proceeds from this offering were approximately $150.4 million after deducting underwriting discounts and commissions but before offering expenses.
  
·Despite the global COVID-19 pandemic, Albireo continues to progress clinical programs and commercial planning, while monitoring the situation closely in anticipation of product filings, approvals and launch in 2021.
  
·Following the AASLD meeting, Albireo will host an investor call on November 17, 2020 to present highlights from the Company’s odevixibat PEDFIC 1 and PEDFIC 2 data presentations. The Company will also highlight data on novel bile acid modulator approaches and A3907, a new product candidate for adult liver diseases.

 

Third Quarter 2020 Financial Results

 

·Revenues were $2.1 million for the third quarter of 2020, compared with $1.4 million for the third quarter of 2019. The higher revenue was due to the estimated royalty revenue received from EA Pharma for elobixibat for the treatment of chronic constipation. The royalty revenue is passed on to HealthCare Royalty Partners.
  
·R&D expenses were $22.2 million for the third quarter of 2020, compared with $12.0 million for the third quarter of 2019. The higher expenses were primarily due to personnel expenses as the Company continues to increase headcount, as well as program expenses related to odevixibat as the Company prepares for regulatory filings and continues to develop additional indications for its lead asset. Continued advancement of preclinical programs also contributed to higher program expenses.
  
·G&A expenses were $11.7 million for the third quarter of 2020, compared with $6.0 million for the third quarter of 2019. The increase was attributable to personnel and related expenses, as the Company continues to increase its headcount and commercialization readiness expenses.
  
·Net loss for the third quarter of 2020 was $30.7 million, or $(1.96) per share, compared with $21.9 million, or $(1.73) per share for the third quarter of 2019.
  
·The Company had cash and cash equivalents on September 30, 2020, of $278.7 million. During the third quarter of 2020, an additional $150.4 million of net proceeds were received from recently completed public financings after deducting underwriting discounts and commissions but before offering expenses. As a result, cash and cash equivalents are anticipated to be sufficient to fully fund the launches of odevixibat and into the revenue generating phase for Albireo.

 

 

 

 

Virtual Business Update Call

 

Albireo will host a post-AASLD event on Tuesday, November 17, 2020, at 10:00 a.m. ET. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13712304. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the Business Update webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo’s website for 2 months following the event.

 

About Odevixibat

 

Odevixibat is an investigational product candidate being developed to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. A highly potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), odevixibat acts locally in the small intestine. Odevixibat does not require refrigeration and can be taken as a capsule for older children, or opened and sprinkled onto food, which are factors of key importance for adherence in a pediatric patient population. The Company announced positive results from the Phase 3 PEDFIC 1 trial with odevixibat in September. Odevixibat is currently being evaluated in the ongoing PEDFIC 2 open-label trial (NCT03659916) in patients with PFIC and the BOLD Phase 3 trial in patients with biliary atresia (NCT04336722). Initiation of a pivotal Phase 3 trial of odevixibat for Alagille syndrome is also anticipated by the end of 2020.

 

Odevixibat has received fast track, rare pediatric disease and orphan drug designations in the United States. In addition, the FDA has granted orphan drug designation to odevixibat for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis. The EMA has granted odevixibat orphan designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. Its Pediatric Committee has agreed to Albireo’s odevixibat Pediatric Investigation Plan for PFIC and biliary atresia. EMA has also granted orphan designation to odevixibat for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis. Odevixibat has the potential to become the first approved drug treatment for patients with PFIC. The Company intends to complete regulatory filings in the EU and U.S. for odevixibat in PFIC no later than early 2021, in anticipation of potential regulatory approval, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021.

 

About Albireo

 

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. The Company expects to complete IND-enabling studies for new preclinical candidate A3907 this year. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

 

 

 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), and the planned pivotal trial for odevixibat in Alagille syndrome; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the long-term open-label extension study for odevixibat in PFIC, the pivotal trial for odevixibat in biliary atresia, the planned pivotal trial for odevixibat in Alagille syndrome; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat, elobixibat, or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential effects of odevixibat of the treatment of PFIC patients and its potential to improve the current standard of care; the potential benefits of an orphan drug designation; the potential issuance of a rare pediatric disease priority review voucher; the period for which Albireo’s cash resources will be sufficient to fund its operating requirements (runway); or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of odevixibat to date, including findings in indications other than PFIC, will be predictive of results from other clinical trials of odevixibat; whether either or both of the FDA and EMA will determine that the primary endpoint for their respective evaluations and treatment duration of the double-blind Phase 3 trial in patients with PFIC are sufficient to support approval of odevixibat in the United States or the European Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of odevixibat, including the pivotal program in biliary atresia or the planned pivotal program in Alagille syndrome, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or European Union; delays or other challenges in the recruitment of patients for, or the conduct of, the double-blind Phase 3 trial or other pivotal trials; and Albireo’s critical accounting policies. These and other risks and uncertainties that Albireo faces are described in greater detail under the heading “Risk Factors” in Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.

 

###

 

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

 

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com

Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com

 

 

 

 

Albireo Pharma, Inc.

 

Condensed Consolidated Balance Sheets

 

(in thousands, except share data)

 

(unaudited)

 

   September 30,   December 31, 
   2020   2019 
Assets        
Current assets:          
Cash and cash equivalents  $278,691   $131,843 
Prepaid expenses and other current assets   8,199    9,956 
Total current assets   286,890    141,799 
Property and equipment, net   551    597 
Goodwill   17,260    17,260 
Other assets   6,401    5,413 
Total assets  $311,102   $165,069 
Liabilities and Stockholders' Equity          
Current liabilities:          
Accounts payable  $3,601   $4,785 
Accrued expenses   16,817    13,486 
Other current liabilities   810    653 
Total current liabilities   21,228    18,924 
Liability related to sale of future royalties   64,871    48,714 
Note payable, net of discount   9,508    — 
Other long-term liabilities   3,735    4,270 
Total liabilities   99,342    71,908 
Stockholders’ Equity:          
Common stock, $0.01 par value per share — 30,000,000 authorized at September 30, 2020 and December 31, 2019; 19,073,498 and 12,749,443 issued and outstanding at September 30, 2020 and December 31, 2019, respectively   190    127 
Additional paid-in capital   451,448    245,769 
Accumulated other comprehensive income   2,143    6,452 
Accumulated deficit   (242,021)   (159,187)
Total stockholders’ equity   211,760    93,161 
Total liabilities and stockholders’ equity  $311,102   $165,069 

 

 

 

 

Albireo Pharma, Inc.

 

Condensed Consolidated Statements of Operations

 

(in thousands, except share and per share data)

 

(unaudited)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2020   2019   2020   2019 
Revenue  $2,131   $1,385   $5,592   $3,205 
Operating expenses:                    
Research and development   22,200    11,996    56,727    31,359 
General and administrative   11,663    6,010    28,290    16,788 
Other operating (income) expense, net   (4,628)   4,015    (4,556)   6,319 
Total operating expenses   29,235    22,021    80,461    54,466 
Operating loss   (27,104)   (20,636)   (74,869)   (51,261)
Interest expense, net   (3,639)   (1,274)   (7,965)   (3,934)
Net loss  $(30,743)  $(21,910)  $(82,834)  $(55,195)
Net loss per common share - basic and diluted  $(1.96)  $(1.73)  $(5.54)  $(4.47)
Weighted-average common shares used to compute basic and diluted net loss per common share   15,704,293    12,685,000    14,942,213    12,349,870 

 

 

 

 EX-101.SCH 3 albo-20200507.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 albo-20200507_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 albo-20200507_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2035067d1_ex99-1img01.jpg GRAPHIC begin 644 tm2035067d1_ex99-1img01.jpg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end XML 7 tm2035067d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001322505 2020-10-05 2020-10-05 iso4217:USD shares iso4217:USD shares 0001322505 false 8-K 2020-11-05 ALBIREO PHARMA, INC. DE 001-33451 90-0136863 10 Post Office Square Suite 1000 Boston MA 02109 857 254-5555 false false false false Common Stock ALBO NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Oct. 05, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 05, 2020
Entity File Number 001-33451
Entity Registrant Name ALBIREO PHARMA, INC.
Entity Central Index Key 0001322505
Entity Tax Identification Number 90-0136863
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 10 Post Office Square
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02109
City Area Code 857
Local Phone Number 254-5555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ALBO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://albireopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2035067d1_8k.htm albo-20200507.xsd albo-20200507_lab.xml albo-20200507_pre.xml tm2035067d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2035067d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2035067d1_8k.htm" ] }, "labelLink": { "local": [ "albo-20200507_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "albo-20200507_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "albo-20200507.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "albo", "nsuri": "http://albireopharma.com/20200507", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035067d1_8k.htm", "contextRef": "From2020-10-05to2020-10-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://albireopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035067d1_8k.htm", "contextRef": "From2020-10-05to2020-10-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://albireopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-20-121584-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-121584-xbrl.zip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end